Relmada Therapeutics, Inc.

RLMD

US75955J4022

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
3.83 ^USD	+3.51%		-4.25%	-7.49%

Mar. 19	Transcript : Relmada Therapeutics, Inc., 2023 Earnings Call, Mar 19, 2024
Mar. 19	Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Relmada Therapeutics, Inc. Announces Resignation of Cedric O?Gorman as Chief Medical Officer

January 03, 2024 at 05:00 pm EST

On January 3, 2024, Dr. Cedric O?Gorman concluded his service as Chief Medical Officer of Relmada Therapeutics, Inc., as mutually agreed upon between him and the Company.

Latest news about Relmada Therapeutics, Inc.

Transcript : Relmada Therapeutics, Inc., 2023 Earnings Call, Mar 19, 2024	Mar. 19
Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Relmada Says Chief Medical Officer Leaving; Names Senior Clinical Development Advisor	Jan. 04	MT
Relmada Therapeutics, Inc. Announces Resignation of Cedric O?Gorman as Chief Medical Officer	Jan. 03	CI
Transcript : Relmada Therapeutics, Inc., Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
Relmada Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Relmada Therapeutics Reports Positive Preclinical Data on its Psilocybin Program to Treat Liver Disease	23-10-11	MT
Relmada Therapeutics to Present New Preclinical Data on Its Psilocybin Program At AASLD the Liver Meeting 2023	23-10-11	CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from S&P Global BMI Index	23-09-18	CI
Relmada Therapeutics, Inc. Announces Eric Schmidt to Resign from the Board, Chairman of the Audit Committee of the Board and as A Member of the Corporate Governance and Nominating Committee of the Board	23-09-06	CI
Relmada Therapeutics Doses First Person in Phase 3 Trial of REL-1017 for Major Depressive Disorder	23-08-23	MT
Relmada Therapeutics, Inc. Announces Dosing of First Patient in Relight, a Phase 3 Trial of Relight, a Phase 3 Trial of Relight for the Adjunctive Treatment of Major Depressive Disorder	23-08-23	CI
Transcript : Relmada Therapeutics, Inc., Q2 2023 Earnings Call, Aug 08, 2023	23-08-08
Relmada Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell 3000 Index	23-06-23	CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell 3000E Value Index	23-06-23	CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell Small Cap Completeness Index	23-06-23	CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell 2500 Index	23-06-23	CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell 2000 Index	23-06-23	CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell 2000 Value Index	23-06-23	CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell Microcap Growth Index	23-06-23	CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell 3000E Growth Index	23-06-23	CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell 3000 Growth Index	23-06-23	CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell 3000E Index	23-06-23	CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell 3000 Value Index	23-06-23	CI

Chart Relmada Therapeutics, Inc.

Duration

Period

More charts

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Companyâs lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.83 USD

Average target price

10.88 USD

Spread / Average Target

+183.94%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
RELMADA THERAPEUTICS, INC.	-7.49%	116M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs